Tomeki

Guidance on the use of rituximab for recurrent or refractory stage III or IV follicular non-Hodgkin's lymphoma

Guidance on the use of rituximab for recurrent or refractory stage III or IV follicular non-Hodgkin's lymphoma

By National Institute for Clinical Excellence.

0 (0 Ratings)
0 Want to read0 Currently reading0 Have read

Publish Date

2002

Publisher

NICE

Language

eng

Pages

17

1-2 of 2 Editions

Guidance on the use of rituximab for recurrent or refractory stage III or IV follicular non-Hodgkin's lymphoma

View Guidance on the use of rituximab for recurrent or refractory stage III or IV follicular non-Hodgkin's lymphoma

Guidance on the use of rituximab for recurrent or refractory stage III or IV follicular non-Hodgkin's lymphoma.

View Guidance on the use of rituximab for recurrent or refractory stage III or IV follicular non-Hodgkin's lymphoma.
Guidance on the use of rituximab for recurrent or refractory stage III or IV follicular non-Hodgkin's lymphoma.

Language: eng

Published In: 2002

Publisher: National Institute for Clinical Excellence